Amendment

In the Specification

Please replace the paragraph on page 23, lines 7-10 with the following amended paragraph:

C1

Examples 15-17 describe experiments demonstrating the increased ~~internal~~ total surface area of porous drug matrices produced with pore forming agents. Examples 18-21 describe experiments demonstrating the advantage or need to include a wetting agent as a component of the porous drug matrices.

Please replace the heading at page 32, lines 20-23 with the following amended heading:

C2

Example 17: ~~Internal~~ Total Surface Area of Porous Drug Matrices Containing a Wetting Agent and Produced With and Without a Pore Forming Agent

Please replace the paragraph at page 32, lines 23-26 with the following amended paragraph:

C3

The ~~internal~~ total surface areas of the drug matrices produced in Examples 15 and 16 were assessed by Krypton BET. BET specific surface area analysis was performed using multi-point surface area analysis with krypton as the gas. Samples were outgassed to 20 micron vacuum at 20 °C prior to analysis.

Please replace the paragraph at page 32, lines 27-29 with the following amended paragraph:

C4

The results, shown in Table 4, illustrate that the use of the pore forming agent led to an increase of between 2.3 and 3.5 fold in the ~~internal~~ total surface area of the resultant drug matrix.

Please replace the heading at page 33, line 1 with the following amended heading:

C5

Table 4: ~~Internal~~ Total Surface Area of Drug Matrices